InvestorsHub Logo
Followers 0
Posts 798
Boards Moderated 0
Alias Born 07/27/2018

Re: boston745 post# 20643

Saturday, 10/27/2018 4:39:23 PM

Saturday, October 27, 2018 4:39:23 PM

Post# of 41802
Thanks for posting this. I had no intentions of reading the transcript. Shots across the bow. Returned fire. Wall street may want to give the impression of not paying attention to these guys. The industry is definitely paying attention. Key note speaker. Seeking expert testimony and consultation.

Interesting use of the words "not wanting to telegraph anything". I will sit here and attempt to glean insight in the way Sintx roles off your tongue.

What's short interest like? That would take a brass pair in my opinion or insider info. at this point. With the name Amedica CTL inherits the website, twitter, youtube from my understanding. Leaving Sintx to build back from the ground up from a company that can't post the conference call transcript. Catch me when I`m falling world. Trust fall.

Interesting you mention Kyocera's azul, Boston. In context with ceramtec defaulting to a Kyocera sales rep. in Japan. It's published that it's Kyocera that was helping the hip study in Japan with the Zimmer plastic liner. Why help your competition in development of a product that competes against Azul? Then answer the phone for Ceramtec sales?

With Ceramtec, Kyocera, Coorstek (Am i forgetting anyone) Ceramicized aluminum oxide femoral heads. None of these violate the Ashok,Bryan Amedica patent for a superior ceramicized Aluminum oxide material? Neither Ashok or Bryan would show licensing/rights royalties for the tech. on dollars for docs. I don't think they have a duty to publish that personally beyond possibly within the Amedica quarterlies. There's a possibility they let it run with Ashok and Bryan royalties and Amedica is not considering it part of their intellectual property. That would be a nice thing to do.

The highest payed doc on dollars for docs takes the licensing and rights royalties. Now CTL's problem to pay the man. Previously he was taking stock, not cash from my understanding. In my mind you got possibly the greatest mind in spinal development tech. taking the stock option, not cash. Interesting.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SINT News